Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

We recently compiled a list of the 7 Best Stocks for Beginners with Little Money According to Analysts. In this article, we ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Approximately 40% of sales were due to doses administered to patients and the remainder were due to inventory building. Merck’s Animal ... of its key products led by Keytruda.

Switzerland’s total lack of patent laws led ... by Merck (MSD). New challenges in an age of innovation The 2010s have seen the development of innovative new classes of medicines, building ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

but it led to higher rates of adverse events, including ones that resulted in death, Merck said. The study tested the pairing against stereotactic body radiotherapy alone. After reviewing the data ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

Merck has a broader product portfolio with more than 52 drugs covering categories like vaccines, hospital acute care, cardiology, virology, and diabetes, but it's clear that Keytruda has led the ...